DGAP-Media / 2020-02-04 / 11:59
*Aladdin Healthcare Technologies SE: Announces we have achieved a top five
position in Kaggle's Global Data Science Bowl 2019*
_(BERLIN, Germany and LONDON, England) 04 February 2020 _*Aladdin Healthcare
Technologies SE ("Aladdin"), is proud to announce that two of its senior
engineers, who are Kaggle Grand Masters, placed 5th out of 3,497 teams in
the prestigious Global Data Science Bowl competition. Again, one of
Aladdin's AI solutions has proven to be at a world class level. A standard
that should set Aladdin on the path to innovation in global healthcare. *
Aladdin's A.I team has achieved a large number of A.I competition 1st prize
awards, including the first prize of 2018 ACM KDD CUP, DCIC 2019. And a
large number of publications, including MICCAI, Nature Machine Intelligence,
IEEE, Bioinformatics etc.
*What is Data Science Bowl (DSB)?*
DSB is the world's largest data science competition focused on social good.
Each year, this competition gives Kagglers a chance to use their passion to
change the world. Over the last four years, more than 50,000+ Kagglers have
submitted over 114,000+ submissions, to improve everything from lung cancer
and heart disease detection to ocean health. DataScienceBowl.com
Reference: https://www.kaggle.com/c/data-science-bowl-2019/leaderboard [1]
Wade Menpes-Smith (Chairman)
About Aladdin Healthcare Technologies SE
Website Link: www.aladdinid.com [2]
WKN: A12ULL
ISIN: DE000A12ULL2
TICKER SYMBOL: NMI
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin
Healthcare Technologies Ltd.) is a leading developer of AI healthcare
diagnostics and drug discovery applications that can accelerate both early
stage disease diagnosis and the end-to-end drug discovery process. Aladdin
targets aged related disease including a significant focus on Alzheimer's
disease. Aladdin accomplishes this by collaborating with numerous partners
within the global healthcare ecosystem to confidentially and securely gather
targeted data including, genome, tabular, MRI, PET, cognition and other
lifestyle data. These datasets are then analysed by our award-winning AI
team and used to develop proprietary AI tools that can assist healthcare
professionals to more accurately and efficiently diagnose aged related
diseases. This new diagnostic process will save significant time and costs
for healthcare professionals. Additionally, our AI drug discovery platform
will be used to by pharmaceutical Companies to speed up drug development,
clinical trials and predict outcomes more accurately.
End of Media Release
Issuer: Aladdin Healthcare Technologies SE
Key word(s): Health
2020-02-04 Dissemination of a Press Release, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Aladdin Healthcare Technologies SE
Unter den Linden 10
10117 Berlin
Germany
Phone: 030 700140449
E-mail: info@aladdinid.com
Internet: www.aladdinid.com
ISIN: DE000A12ULL2
WKN: A12ULL
Listed: Regulated Market in Dusseldorf
EQS News ID: 967319
End of News DGAP Media
967319 2020-02-04
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=0fd48819442f96cd12d53af1e66b30d0&application_id=967319&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=a2dd1bbc615be83abe8f7699163b31b0&application_id=967319&site_id=vwd&application_name=news
(END) Dow Jones Newswires
February 04, 2020 05:59 ET (10:59 GMT)
© 2020 Dow Jones News
